Literature DB >> 22699400

The gastrointestinal pharmacology of cannabinoids: focus on motility.

Raquel Abalo1, Gema Vera, Ana Esther López-Pérez, María Martínez-Villaluenga, María Isabel Martín-Fontelles.   

Abstract

The marijuana plant Cannabis sp. and its derivatives and analogues, known as cannabinoids (CBs), induce many effects throughout the whole body. Herein we briefly review the gastrointestinal (GI) pharmacology of CBs, with special focus on motor function. Some drugs are available to treat nausea and emesis, and evidences in humans and animal models suggest that other GI motility alterations (gastro-oesophageal reflux, inflammatory bowel conditions or paralytic ileus) might benefit from modifications of the CB tone throughout the gut. However, central and peripheral (including GI) side effects may occur upon acute and chronic CB administration. Hopefully, the ongoing worldwide intense research on CBs will soon provide new, safer CB-based medicines.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699400     DOI: 10.1159/000339072

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  16 in total

Review 1.  The Impact of Perioperative Cannabis Use: A Narrative Scoping Review.

Authors:  Karim S Ladha; Varuna Manoo; Ali-Faizan Virji; John G Hanlon; Alexander Mclaren-Blades; Akash Goel; Duminda N Wijeysundera; Lakshmi P Kotra; Carlos Ibarra; Marina Englesakis; Hance Clarke
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-06

Review 2.  Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review.

Authors:  Cecilia J Sorensen; Kristen DeSanto; Laura Borgelt; Kristina T Phillips; Andrew A Monte
Journal:  J Med Toxicol       Date:  2016-12-20

3.  Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation.

Authors:  M Bashashati; Y Nasser; C M Keenan; W Ho; F Piscitelli; M Nalli; K Mackie; M A Storr; V Di Marzo; K A Sharkey
Journal:  Br J Pharmacol       Date:  2015-04-23       Impact factor: 8.739

4.  AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner.

Authors:  C M Keenan; M A Storr; G A Thakur; J T Wood; J Wager-Miller; A Straiker; M R Eno; S P Nikas; M Bashashati; H Hu; K Mackie; A Makriyannis; K A Sharkey
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

5.  In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.

Authors:  R Abalo; C Chen; G Vera; J Fichna; G A Thakur; A E López-Pérez; A Makriyannis; M I Martín-Fontelles; M Storr
Journal:  Neurogastroenterol Motil       Date:  2015-09-20       Impact factor: 3.598

Review 6.  Cannabinoids and GI Disorders: Endogenous and Exogenous.

Authors:  Zachary Wilmer Reichenbach; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

Review 7.  The Role of the Endocannabinoid System in the Brain-Gut Axis.

Authors:  Keith A Sharkey; John W Wiley
Journal:  Gastroenterology       Date:  2016-04-29       Impact factor: 22.682

8.  Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2.

Authors:  Elżbieta Radziszewska; Ewa Bojanowska
Journal:  Med Sci Monit Basic Res       Date:  2013-01-01

Review 9.  Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments.

Authors:  Rachel M McQuade; Vanesa Stojanovska; Raquel Abalo; Joel C Bornstein; Kulmira Nurgali
Journal:  Front Pharmacol       Date:  2016-11-03       Impact factor: 5.810

10.  Involvement of Cannabinoid Signaling in Vincristine-Induced Gastrointestinal Dysmotility in the Rat.

Authors:  Gema Vera; Ana E López-Pérez; José A Uranga; Rocío Girón; Ma Isabel Martín-Fontelles; Raquel Abalo
Journal:  Front Pharmacol       Date:  2017-02-06       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.